Q Fever - Pipeline Review, H1 2016 Summary Global Markets Direct's, 'Q Fever - Pipeline Review, H1 2016', provides an overview of the Q Fever pipeline landscape. The report provides comprehensive information on the therapeutics under development for Q Fever, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Q Fever and features dormant and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data. Scope - The report provides a snapshot of the global therapeutic landscape of Q Fever - The report reviews pipeline therapeutics for Q Fever by companies and universities/research institutes based on information derived from company and industry-specific sources - The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages - The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved Q Fever therapeutics and enlists all their major and minor projects - The report assesses Q Fever therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type - The report summarizes all the dormant and discontinued pipeline projects - The report reviews latest news related to pipeline therapeutics for Q Fever Reasons To Buy - Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Identify and understand important and diverse types of therapeutics under development for Q Fever - Identify potential new clients or partners in the target demographic - Develop strategic initiatives by understanding the focus areas of leading companies - Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics - Devise corrective measures for pipeline projects by understanding Q Fever pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents
Table of Contents 2 List of Tables 4 List of Figures 5 Introduction 6 Global Markets Direct Report Coverage 6 Q Fever Overview 7 Therapeutics Development 8 Pipeline Products for Q Fever - Overview 8 Pipeline Products for Q Fever - Comparative Analysis 9 Q Fever - Therapeutics under Development by Companies 10 Q Fever - Therapeutics under Investigation by Universities/Institutes 11 Q Fever - Pipeline Products Glance 12 Clinical Stage Products 12 Early Stage Products 13 Q Fever - Products under Development by Companies 14 Q Fever - Products under Investigation by Universities/Institutes 15 Q Fever - Companies Involved in Therapeutics Development 16 Aradigm Corporation 16 Grifols, S.A. 17 Q Fever - Therapeutics Assessment 18 Assessment by Monotherapy Products 18 Assessment by Target 19 Assessment by Mechanism of Action 21 Assessment by Route of Administration 23 Assessment by Molecule Type 25 Drug Profiles 27 ARD-3100 - Drug Profile 27 Product Description 27 Mechanism of Action 27 R&D Progress 27 ARD-3150 - Drug Profile 29 Product Description 29 Mechanism of Action 29 R&D Progress 29 ciprofloxacin hydrochloride - Drug Profile 31 Product Description 31 Mechanism of Action 31 R&D Progress 31 Monoclonal Antibodies to Inhibit PD-1/PD-L1 for Hematological Malignancies and Bacterial Infections - Drug Profile 32 Product Description 32 Mechanism of Action 32 R&D Progress 32 NDBR-105 - Drug Profile 33 Product Description 33 Mechanism of Action 33 R&D Progress 33 q fever vaccine - Drug Profile 34 Product Description 34 Mechanism of Action 34 R&D Progress 34 Q Fever - Recent Pipeline Updates 35 Q Fever - Product Development Milestones 42 Featured News & Press Releases 42 Sep 20, 2012: UK Scientists Report Successful Testing Of Aradigm's Inhaled Liposomal Ciprofloxacin In Q Fever 42 Appendix 43 Methodology 43 Coverage 43 Secondary Research 43 Primary Research 43 Expert Panel Validation 43 Contact Us 43 Disclaimer 44
List of Tables
Number of Products under Development for Q Fever, H1 2016 8 Number of Products under Development for Q Fever - Comparative Analysis, H1 2016 9 Number of Products under Development by Companies, H1 2016 10 Number of Products under Investigation by Universities/Institutes, H1 2016 11 Comparative Analysis by Clinical Stage Development, H1 2016 12 Comparative Analysis by Early Stage Development, H1 2016 13 Products under Development by Companies, H1 2016 14 Products under Investigation by Universities/Institutes, H1 2016 15 Q Fever - Pipeline by Aradigm Corporation, H1 2016 16 Q Fever - Pipeline by Grifols, S.A., H1 2016 17 Assessment by Monotherapy Products, H1 2016 18 Number of Products by Stage and Target, H1 2016 20 Number of Products by Stage and Mechanism of Action, H1 2016 22 Number of Products by Stage and Route of Administration, H1 2016 24 Number of Products by Stage and Molecule Type, H1 2016 26 Q Fever Therapeutics - Recent Pipeline Updates, H1 2016 35
Our library has over 100000 reports on 1000s of topics
Over 100+ Fortune 500 companies rely on us
90,000+ people come to us for insights every month
Toll Free: 1-888-928-9744
Email: [email protected]
Speak to the report author to design an exclusive study to serve your research needs.
A testimonial for service excellence represented in the form of BBB "A" Accreditation.
Your personal and confidential information is safe and secure.